Physician profile
Shravan Kandula
NPI 1477870780
$443,784.50
in general payments reported to CMS, 2019-2025
26 companies · $59K in 2025
The $59K reported for 2025 was more than what 99% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,968 · 2020: $10K · 2021: $114K · 2022: $115K · 2023: $65K · 2024: $71K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Consulting Fee: $33K · Travel and Lodging: $26K · Food and Beverage: $6,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,580.67 |
| Consulting Fee | $33,408.60 |
| Travel and Lodging | $26,471.65 |
| Food and Beverage | $6,616.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $300,288.87 | 2019-2025 | Libtayo |
| Genzyme Corporation | $97,507.82 | 2019-2022 | |
| Coherus Oncology, INC. | $22,426.89 | 2022-2025 | Loqtorzi |
| Regeneron Pharmaceuticals, INC. | $21,000.21 | 2024-2025 | Libtayo |
| Brainlab, INC. | $1,037.47 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $473.71 | 2022-2024 | Myrisk, Precisetumor |
| Siemens Medical Solutions USA, INC. | $173.24 | 2021 | |
| Teleflex LLC | $135.91 | 2025 | Barrigel |
| Novartis Pharmaceuticals Corporation | $104.51 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $60.12 | 2025 | Keytruda, Keytruda Qlex |
| Sumitomo Pharma America, INC. | $57.96 | 2024-2025 | Orgovyx |
| Icotec Medical INC. | $57.92 | 2025 | Kong-Tl Vbr, End Plate, Round, L and Screw, 12 X 43 Mm, Kong-Tl Vbr, End Plate, Rectangular, M and Screw, 12 X 33 Mm, Kong-Tl Vbr E, Expandable Body, L, 19 Mm X 27 - 37 Mm |
| Astrazeneca Pharmaceuticals Lp | $56.65 | 2024-2025 | Imfinzi |
| Boston Scientific Corporation | $50.64 | 2019-2020 | |
| Tactile Systems Technology INC | $49.70 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $44.33 | 2024-2025 | Optune, Optune Gio |
| Tolmar, INC. | $44.20 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $44.20 | 2025 | Rubraca |
| Ambu INC. | $33.93 | 2022 | |
| Lilly USA, LLC | $28.17 | 2023 | Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $26.74 | 2023 | |
| Servier Pharmaceuticals LLC | $22.93 | 2025 | |
| Napo Pharmaceuticals INC | $20.54 | 2025 | Gelclair Concentrated Oral Gel |
| Incyte Corporation | $19.47 | 2023 | Jakafi |
| Fortovia Therapeutics, INC. | $18.37 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shravan Kandula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.